Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2018 | Update on bb2121 CAR T-cell product for MM from EHA 2018

Jesús Berdeja • 15 Jun 2018
EHA 2018
Multiple Myeloma CAR-T Idecabtagene vicleucel

Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús Berdeja of the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, gives an update on idecabtagene vicleucel (formerly bb2121), a promising therapy for patients with heavily pre-treated relapsed/refractory multiple myeloma (MM).

More from Jesús Berdeja

Multiple myeloma highlights at ASH 2020 1:22
Multiple myeloma highlights at ASH 2020
Jesús Berdeja • 11 Dec 2020
CRB-402 study update: T-cell phenotypes in myeloma 2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020
Impact of age on ide-cel efficacy in the KarMMa trial 1:55
Impact of age on ide-cel efficacy in the KarMMa trial
Jesús Berdeja • 11 Dec 2020
Update on CARTITUDE-1: CAR-T in RRMM 4:10
Update on CARTITUDE-1: CAR-T in RRMM
Jesús Berdeja • 26 May 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals